New Product Launch VETRANO®palbociclib

c28002612026-01-27T18:20:41+00:00 We are thrilled to present to our community the launch of the product VETRANO® palbociclib, for our Oncology Line. VETRANO® palbociclib is indicated for the treatment of hormone receptor positive (HR+) and human epidermal growth factor receptor 2 (HER2-) negative, metastatic or locally advanced...

New Product Lunch TSUMIS®Carfilzomib

c28002612026-01-28T12:13:44+00:00 Bioprofarma Bagó is pleased to present the launch of the product TSUMIS® carfilzomib, for its Hematology Line. TSUMIS® carfilzomib is approved by ANMAT, in combination with daratumumab and dexamethasone, lenalidomide and dexamethasone or dexamethasone alone, for the treatment of adult patients with multiple myeloma...

New Product Launch DALCARA®sorafenib

c28002612026-01-28T12:29:53+00:00 At Bioprofarma Bagó, we are excited to present the launch of the product DALCARA® sorafenib, for our Oncology Business Unit. DALCARA® sorafenib is approved by ANMAT for:- the treatment of liver cancer (hepatocellular carcinoma);- the treatment of advanced stage renal cancer (advanced renal cell...

New Product Launch GOMBRICH®cabazitaxel

c28002612026-04-17T18:26:06+00:00 Bioprofarma Bagó is proud to present the launch of GOMBRICH® cabazitaxel, for its Oncology Business Unit. GOMBRICH® cabazitaxel is used for the treatment of prostate cancer that has progressed after having received other chemotherapy. It works by stopping cell growth and multiplication. GOMBRICH® cabazitaxel is...

New Product Launch BIOPONIB®ponatinib

c28002612026-01-29T12:49:26+00:00 Bioprofarma Bagó is pleased to present the launch of BIOPONIB® ponatinib for its Hematology Business Unit. BIOPONIB® ponatinib is approved by ANMAT for the treatment of Chronic Myeloid Leukemia (CML) and Philadelphia chromosome positive Acute Lymphoblastic Leukemia (Ph+ ALL) in adult patients who are resistant...

NEW PRODUCT LAUNCH ANTIXAN® edaravone

c28002612026-01-29T19:24:43+00:00 ANTIXAN® edaravone is approved by ANMAT for the following indications: Inhibition in the progression of functional disorders in patients with Amyotrophic Lateral Seclerosis (ALS) Improve neurological symptoms, disorders in daily activities. PRESENTATION: 30 mg x 10 injection

NEW LAUNCH: CarciVac®, vaccine onco BCG

c28002612026-01-29T22:11:22+00:00 Bioprofarma Bagó presents CarciVac® for the treatment of non-muscle invasive bladder cancer. We are pleased to announce the launch of CarciVac® vaccine onco BCG Bacilo Calmette-Guérin. This product complements our Urology portfolio continuing our commitment to patients suffering bladder cancer. CarciVac® is manufactured by Serum Institute of...